GATA1

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
GATA binding protein 1 (globin transcription factor 1)
Identifiers
Symbol GATA1
Alt. Symbols GF1 NFE1 ERYF1
Entrez 2623
HUGO 4170
OMIM 305371
RefSeq NM_002049
UniProt P15976
Other data
Locus Chr. X p11.23

GATA1 is an important transcription factor involved in cell growth and cancer.

It is essential for erythroid(red blood cell) and megakaryocytic development and mice without GATA1 die as embryos. It helps transcribe the α-spectrin structural protein which is critical for the shape of red blood cells.

The molecule contains three domains the C-finger the N-finger and the Activation Domain. The C-finger, named for being near the C-terminal, has a Zinc finger DNA binding domain. The N-finger, named for being near the N-terminal also binds DNA and a cofactor named FOG-1. The Activation Domain is responsible for GATA1's strong transcriptional activation. The gene for GATA1 is on the X-chromosome.

It has been found to enhance the transcription rates by up to 100 times in humans[1].

In 2002, Wechsler J et al[1] demonstrated mutations in exon 2 of the GATA1 gene present in almost all cases of Down syndrome (DS)-associated acute megakaryoblastic leukemia (AMKL).[1]. While AMKL is typically associated with the 1;22 translocation and expression of a mutant fusion protein, the genetic alterations that promote individuals with DS-AMKL are related to the GATA1 mutations, and the formation of a truncated transcription factor (GATA1s). In 2003, Greene et al showed the same mutations in exon 2 of GATA1 present in almost all Down Syndrome-associated transient myeloproliferative disorder (TMD) or transient leukemia (TL), a precursor condition that evolves into AMKL in 30% of patients, that as many as 10% of Down Syndrome children may develop. Pine SR et al demostrated an incidence for the GATA1 mutation in about 4% of Down Syndrome patients tested, but less than 10% of those with the mutation developed AMKL. Shimada et al. showed in 2004 that the mutation is present in the fetus, suggesting an early role in leukemogenesis. In addition to screening for TL, a GATA1 mutation at birth might serve as a bio-marker for an increased risk of DS-related AMKL.

References

External links

WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch



Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools